Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to tr…
Drug Manufacturers - General
US, Thousand Oaks [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | 29.43 | 88.08 | 68.05 | |
| Graham Fair Price | -65.61 | 6.67 | 19.38 | |
| PEG | 224.72 | 2.93 | -0.90 | |
| Price/Book | 22.18 | 30.21 | 24.73 | |
| Price/Cash Flow | -38.01 | 330.52 | 533.19 | |
| Prices/Earnings | 568.27 | -335.64 | 50.23 | |
| Price/Sales | 9.10 | 20.51 | 18.80 | |
| Price/FCF | -38.01 | 330.52 | 533.19 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Bad
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | -8.54 | 0.57 | 0.62 | |
| Operating Margin | -18.04 | 0.13 | 0.16 | |
| ROA | -84.61 | < 0.005 | < 0.005 | |
| ROE | 0.12 | -0.02 | -81.72 | |
| ROIC | 0.02 | 0.02 | 40.09 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | < 0.005 | 0.07 | -86.61 | |
| Dividends QOQ | 0.00 | 0.06 | 100.00 | |
| EBIT QOQ | -0.37 | -0.26 | 29.82 | |
| EPS QOQ | -0.56 | -1.15 | -105.80 | |
| FCF QOQ | -0.88 | 0.59 | -33.53 | |
| Revenue QOQ | 0.19 | -0.10 | -47.89 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Balanced
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 275.26 | 245.36 | -10.86 | |
| Days Sales Outstanding (DSO) | 87.21 | 82.46 | -5.45 | |
| Inventory Turnover | 0.33 | 0.37 | 12.19 | |
| Debt/Capitalization | 0.91 | 0.93 | 1.67 | |
| Quick Ratio | 1.62 | 0.84 | -48.45 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Bad
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 11.65 | 9.37 | -19.57 | |
| Cash | 40.91 | 18.11 | -55.73 | |
| Capex | -0.47 | -0.43 | 7.80 | |
| Free Cash Flow | 0.54 | 0.86 | 58.53 | |
| Revenue | 15.32 | 13.80 | -9.93 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Weak
Fundamentals
Financial Health
06 - Financial Health ·
Weak